(4-chlorophenyl)(2-(trifluoromethyl)phenyl)methanol | 89664-09-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-chlorophenyl)(2-(trifluoromethyl)phenyl)methanol
• 英文别名: alpha-(4-Chlorophenyl)-2-(trifluoromethyl)benzyl alcohol；(4-chlorophenyl)-[2-(trifluoromethyl)phenyl]methanol
• CAS: 89664-09-5
• 化学式: C₁₄H₁₀ClF₃O
• 分子量: 286.681
• InChiKey: STNOYOGONSFCSX-UHFFFAOYSA-N

物化性质

• 沸点：
  354.7±37.0 °C(Predicted)
• 密度：
  1.348±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (4-chlorophenyl)(2-(trifluoromethyl)phenyl)methanol 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 生成 C₁₄H₉Cl₂F₃
  参考文献：
  名称：

  Design, synthesis and biological evaluation of piperazine analogues as CB1 cannabinoid receptor ligands

  摘要：

  After the CB1 receptor antagonist SR141716 (rimonabant) was previously reported to modulate food intake, CB1 antagonism has been considered as a new therapeutic target for the treatment of obesity. Several series of urea, carbamate, amide, sulfonamide and oxalamide derivatives based on 1-benzhydrylpiperazine scaffold were synthesized and tested for CB1 receptor binding affinity. The SAR studies to optimize the CB1 binding affinity led to the potent urea derivatives. After the additional SAR studies to optimize the substituents of diphenyl rings, the combination of 2-chlorophenyl and 4-chlorophenyl turned out to be the most potent scaffold. The CB2 binding affinity assay as well as functional assay was also conducted on these compounds. Herein we wish to introduce several novel CB1 antagonists with IC50 values less than 100 nM for the CB1 receptor binding. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.01.023
• 作为产物：
  描述：

  邻溴三氟甲苯 在 lithium chloro-isopropyl-magnesium chloride 作用下， 以 四氢呋喃 为溶剂， 反应 6.0h， 生成 (4-chlorophenyl)(2-(trifluoromethyl)phenyl)methanol
  参考文献：
  名称：

  Online and In Situ Monitoring of the Exchange, Transmetalation, and Cross-Coupling of a Negishi Reaction

  摘要：

  DOI：

  10.1021/acs.oprd.2c00081

文献信息

• [EN] AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDRS<br/>[FR] DERIVES AZETIDINECARBOXAMIDE ET LEUR UTILISATION POUR LE TRAITEMENT DE TROUBLES A MEDIATION DU RECEPTEUR DU CB1
  申请人：VERNALIS RES LTD

  公开号：WO2004096794A1

  公开（公告）日：2004-11-11

  Compounds of formula (I) and their use in therapy, particularly for the treatment of a disorder mediated by CB1 receptors, such as obesity, wherein: R1 is aryl or heteroaryl; R2 is alkyl, aryl or heteroaryl; R3 is alkyl, aryl, heteroaryl, NR9R10, OR 15, or NR 16C(O)R17; Y is C=O, C=S, SO2, or (CR7R8)p; m = 1 or 2; n = 1 or 2; and p=1,2,3 or 4, R7 to R17 being as defined in the specification; wherein if -Y-R3 is -C(O)NH(alkyl) then: R1 and/or R2 is selected from heteroary1; and/or m and/or n is 2; and/or R11 and/or R12 is lower alkyl, or a pharmaceutically acceptable salt or prodrug thereof.

  化合物的化学式（I）及其在治疗中的应用，特别是用于治疗由CB1受体介导的疾病，如肥胖，其中：R1为芳基或杂环芳基；R2为烷基，芳基或杂环芳基；R3为烷基，芳基，杂环芳基，NR9R10，OR 15，或NR 16C(O)R17；Y为C=O，C=S，SO2，或（CR7R8）p；m = 1或2；n = 1或2；p=1,2,3或4，R7到R17如规范中定义；其中如果-Y-R3为-C(O)NH(烷基)则：R1和/或R2从杂芳基中选择；和/或m和/或n为2；和/或R11和/或R12为较低烷基，或其药用盐或前药。
• CuCl/Bipyridine-Catalyzed Addition Reactions of Arylboroxines with Aldehydes, α,β-Unsaturated Ketones, and <i>N</i>-Tosyl Aldimines
  作者：Yuan-Xi Liao、Qiao-Sheng Hu

  DOI：10.1021/jo201338v

  日期：2011.9.16

  CuCl/bipyridine-catalyzed addition reactions of arylboroxines with aldehydes and α,β-unsaturated ketones at elevated temperatures were described. By using the microwave energy, CuCl/bipyridine-catalyzed addition reactions of arylboroxines with aldimines were also realized.

  描述了CuCl /联吡啶催化芳基硼氧烷与醛和α，β-不饱和酮在高温下的加成反应。通过使用微波能量，还实现了CuCl /联吡啶催化的芳基硼氧烷与醛亚胺的加成反应。
• [EN] AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS<br/>[FR] DERIVES D'AZETIDINECARBOXAMIDE ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES MEDIES PAR LES RECEPTEUR CB1
  申请人：VERNALIS RES LTD

  公开号：WO2004096763A1

  公开（公告）日：2004-11-11

  Compounds of formula (I) and their use in therapy, particularly for the treatment of a disorder mediated by CB1 receptors such as obesity: Formuila (I) wherein: R1 and R2 are independently selected from aryl; and R3 is hydrogen or alkyl; or a pharmaceutically acceptable salt or prodrug thereof, wherein at least one of R1 and R2 has a non-hydrogen substituent in the ortho-position(s) thereof relative to the point of attachment to the [-CH-0-] group.

  式(I)化合物及其在治疗中的应用，特别用于治疗由CB1受体介导的疾病，如肥胖症：式(I)中：R1和R2各自独立地选自芳基；R3为氢或烷基；或其药学上可接受的盐或前药，其中R1和R2中至少一个在相对于与[-CH-0-]基团连接点的邻位上具有非氢取代基。
• Convenient Synthesis of Structurally Novel 1,3‐Disubstituted Azetidine Derivatives
  作者：Rajendra K. Kharul、Amitgiri Goswami、Archana Gite、Atul K. Godha、Mukul Jain、Pankaj R. Patel

  DOI：10.1080/00397910801982340

  日期：2008.5

  Abstract A convenient synthesis of structurally novel 1,3‐disubstituted azetidine derivatives is described. The approach involves condensation of an azetidine building block with sulfonylated carbamic acid methyl ester, subsequently followed by quenching the imidoyl chloride with amines. Different derivatives were prepared by substituting benzhydrol as well as benzenesulfonamide as part of the core

  摘要描述了结构新颖的 1,3-二取代氮杂环丁烷衍生物的方便合成。该方法涉及将氮杂环丁烷结构单元与磺酰化氨基甲酸甲酯缩合，随后用胺猝灭亚氨酰氯。通过取代二苯甲醇和苯磺酰胺作为核心结构的一部分来制备不同的衍生物。
• Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disordrs
  申请人：Davidson Edward Paul James

  公开号：US20070173486A1

  公开（公告）日：2007-07-26

  Compounds of formula (I) and their use in therapy, particularly for the treatment of a disorder mediated by CB 1 receptors, such as obesity, wherein: R 1 is aryl or heteroaryl; R 2 is alkyl, aryl or heteroaryl; R 3 is alkyl, aryl, heteroaryl, NR 9 R 10 , OR 15 , or NR 16 C(O)R 17 ; Y is C═O, C═S, SO 2 , or (CR 7 R 8 ); m=1 or 2; n=1 or 2; and p=1, 2, 3 or 4, R 7 to R 17 being as defined in the specification; wherein if —Y—R 3 is —C(O)NH(alkyl) then: R 1 and/or R 2 is selected from heteroaryl; and/or m and/or n is 2; and/or R 11 and/or R 12 is lower alkyl, or a pharmaceutically acceptable salt or prodrug thereof.

  式(I)的化合物及其在治疗中的用途，特别是用于治疗由CB1受体介导的疾病，例如肥胖症，其中：R1为芳基或杂环芳基；R2为烷基，芳基或杂环芳基；R3为烷基，芳基，杂环芳基，NR9R10，OR15或NR16C（O）R17；Y为C═O，C═S，SO2或（CR7R8）；m=1或2；n=1或2；p=1、2、3或4，R7到R17如规范所定义；如果—Y—R3为—C（O）NH（烷基），则：R1和/或R2选自杂环芳基；和/或m和/或n为2；和/或R11和/或R12为较低的烷基，或其药学上可接受的盐或前药。